Mission Statement
Anthera Pharmaceuticals is a privately held pharmaceutical company committed to world-class development and commercialization of promising clinical products to address the unmet medical needs of patients with life–threatening inflammatory diseases.
Our Strategy
In order to efficiently commercialize its platform of potent anti-inflammatory products, Anthera has brought together a world-class development team with extensive experience in developing, licensing, and commercializing anti-inflammatory products for unmet medical needs.
Read More
Current Clinical Trials:
Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome
(IMPACTS Trial Site)
Phospholipase Levels And Serological Markers of Atherosclerosis
(PLASMA Trial Site)
Phospholipase Levels And Serological Markers of Atherosclerosis 2
(PLASMA 2 Trial Site)
Press Releases
April 17‚ 2008
Anthera presents data on Varespladib at ATVB meeting
April 16‚ 2008
DSMB supports continuation of Anthera phase II IMPACTS trial for the prevention of acute chest syndrome in patients with sickle cell disease
February 7‚ 2008
Data From Anthera's PLASMA Trial to be Presented as Late Breaker at American College of Cardiology Scientific Sessions.
Anthera Raises Money for Children’s Hospital Oakland Research Institute.
Read More